Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy

17 Nov 2022

Abstract excerpt

BACKGROUND: Improvement of efficacy of immune checkpoint blockade (ICB) remains a major clinical goal. Association of ICB with immunomodulatory epigenetic drugs is an option. However, epigenetic inhibitors show a heterogeneous landscape of activities. Analysis of transcriptional programs induced in neoplastic cells by distinct classes of epigenetic drugs may foster identification of the most promising agents....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36397155
DOI: 10.1186/s13046-022-02529-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapyPMID 36397155Read ↗

Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy.Semantic proximity Read ↗

Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapySemantic proximity Read ↗

Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and correlation with integrated, multiomic analysis in the NIBIT-M4 trialSemantic proximity Read ↗

Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling the responses of T-cells, myeloid derived suppressor cells and NK cellsSemantic proximity Read ↗

DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapySemantic proximity Read ↗

Decitabine reverses innate immune gene suppression in rare melanomasSemantic proximity Read ↗

DNA methylation variations of DNA damage response correlate survival and local immune status in melanomas.Semantic proximity Read ↗

Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapySemantic proximity Read ↗

Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy ResistanceSemantic proximity Read ↗

Checkpoint-blocker induced autoimmunity is associated with pretreatment T cell expression profiles and favourable outcome in melanomaSemantic proximity Read ↗

Role of Histone Deacetylases in Drug-Resistant Melanoma: Mechanisms and Therapeutic ImplicationsSemantic proximity Read ↗

Epigenetic modulation reveals differentiation state specificity of oncogene addictionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.